|
|
|
|
Generic Names of Some Trade Name Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs -~ Generic Names of Some Trade Name Drugs - Generic Names of Some...
|
|
|
Some Trade Names of Generic Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs-~ Generic Names of Some Trade Name Drugs - Some Trade Names of...
|
|
|
Genentech: Investor Relations - Financials - 2001 First Quarter Report
Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2001 First Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
|
|
|
Genentech: About Us - Corporate Overview - Corporate Growth Strategy
Home Contact Us Site Index Search [ About Us -- Corporate Overview -- Corporate Growth Strategy -- 5X5 Goals ] Corporate Overview Home History Awards & Recognition Corporate Growth Strategy 5x5 Goals--- Horizon 2010 Compliance Programs 5X5 Goals Our 5X5 goals began in 1999 and continue in place through 2005.
5 new products/indications approved With the nine approvals of Nutropin...
|
|
|
Genentech: Investor Relations - Financials - 2000 Second Quarter Report
As expected, we launched TNKase™ (Tenecteplase) and Nutropin Depot™ [somatropin (rDNA origin) for injectable suspension] late in the quarter and that did not materially affect Q2 sales, but we do expect to strengthen both our cardiovascular and growth hormone franchises with the introduction of these two products.
Product News On June 2, TNKase was...
|
|
|
Genentech: Investor Relations - Financials - 2001 Third Quarter Report
Home Contact Us Site Index Search [ Investors -- Financials -- Quarterly Reports -- 2001 Third Quarter Report ] Investors Home Calendar of Events Contacts Corporate Governance E-Delivery of Annual Report E-Mail Alerts Fact Sheet FAQs Financials Annual Reports Quarterly Reports--- Earnings Releases GAAP vs Non-GAAP Reconciliation Other Income, Net Historical Product Sales 11-Year...
|
|
|
Genentech: Products - Product Information - TNKase
Home Contact Us Site Index Search [ Products -- TNKase ] Products Home ONCOLOGY Avastin Herceptin Rituxan Tarceva IMMUNOLOGY Raptiva Xolair VASCULAR MEDICINE Activase Cathflo Activase TNKase Full Prescribing Information TNKase Fact Sheet The Future of Heart Attack Treatment Heart Attack Fact Sheet TNKase Mechanism of Action SPECIALTY BIOTHERAPEUTICS Nutropin...
|
|
|
Oncology, Immunological Disease, Vascular Medicine and Biotherapeutics information
Immunology RAPTIVA® (efalizumab) Anti-CD11a antibody For chronic moderate-to-severe plaque psoriasis in adults age 18 or older Xolair® (Omalizumab) for Subcutaneous Use Anti-IgE antibody For moderate-to-severe persistent asthma in adults and adolescents Vascular Medicine Activase® (Alteplase) A tissue-plasminogen activator For acute myocardial infarction, acute ischemic...
|
|
|
SY161, a cost-effective treatment of acute myocardial infarction
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
|
|
|
http://www.gene.com/gene/products/information/pdf/tnkase-mediaalert.pdf
Media Alert BI Media Contact: Ute Schmidt +49- 61- 32- 779- 7296 Genentech Media Contact: Marites Cristobal 650- 225- 8226 Dawn Kalmar 650- 225- 5873 BOEHRINGER INGELHEIM AND GENENTECH ANNOUNCE EARLY TERMINATION OF A PHASE IIIb/ IV STUDY OF TNKASE/ METALYSE USED PRIOR TO ANGIOPLASTY IN PATIENTS WITH SEVERE HEART ATTACKS Ingelheim, Germany and South San Francisco, Calif.
...
author: Genentech, Inc.
|
|
|
untitled
3 5 new products/ indications approved We have already exceeded our 5X5 goal of five new products or indications approved, with eight products or indications approved since 1999: Nutropin Depot ® [somatropin (rDNA origin) for injection], TNKase ª (Tenecteplase), Cathflo ® Activase ® (Alteplase), Nutropin AQ Pen ® (a delivery system), Xolair ®...
|
|
|
Database T
T - investigational drugs, therapies and vaccines # - A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z From this page you may order documents with information covering investigational products To purchase documents on-line click on -link attached to selected document!- The fee is $15 per document Documents are delivered by e-mail...
|
|
|
22723txt
We let the science lead us
Both projects are key to our short- and long- term strategy to maximize our manufacturing capacities and meet demand for our products
25 percent average annual non- GAAP 1 EPS growth The first goal is the most important of the 5X5 goals
500 $347 2001 2002 2003 400 100 200 300 $385 $425 Herceptin Sales Combined net sales of our three thrombolytic...
author: amag4-pickle
|
|
|
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf
We own or have rights to various copyrights, trademarks and trade names used in our business including the following: Activase ® (alteplase, recombinant) tissue- plasminogen activator; Avastin ’ (bevacizumab) anti- VEGF antibody; Cathflo ® Activase ® (alteplase for catheter clearance); Herceptin ® (trastuzumab) anti- HER2 antibody; Lucentis ’ ...
|
|
|
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/form10k.pdf page 5
|
|
|
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/financialhighlights.pdf
genentech 8 % CHANGE FROM PRECEDING YEAR YEARS ENDED DECEMBER 31, 2003 2002 2001 2003/ 2002 2002/ 2001 Total operating revenues $3, 300.2 $2, 583.7 $2, 044.1 28% 26% Product sales 2, 621.4 2, 163.6 1, 742.9 21 24 Cost of sales (COS) 480.1 441.6 354.5 9 25 Research and development (R& D) expenses 722.0 623.5 526.2 16 18 R& D expenses as a % of operating revenues 22% 24% 26% N N...
|
|
|
http://www.gene.com/gene/ir/financials/annual-reports/2003/financials/financialhighlights.pdf page 2
|
|
|
Therapeutic Biological Approvals
FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - -Therapeutic Biological Approvals - Tradename/ Proper Name Indication for Use STN Manufacturer/ License No
97 South Street Hopkinton, MA 01748 License 1258 02/05/1999 PEGASYS Peginterferon alfa-2a Treatment of adults with chronic hepatitis C who have compensated liver disease and who have...
|
|
|
Tenecteplase - Product Approval Information - Licensing Action
FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER - Search - -Tenecteplase Product Approval Information - Licensing Action Proper name: Tenecteplase Tradename: TNKase Manufacturer: Genentech, Inc, South San Francisco, CA, License #1048 Indication for Use: Reduction of mortality associated with acute myocardial infarction (AMI)...
|
|
|
Prescription Drug User Fee Act - User Fee Billable Therapeutic Products: Approved Under Section 351 of the PHS Act
IU/mL Corixa Corp License 1614 Bexxar Tositumomab and Iodine I-131 Tositumomab 125011/0 6/27/2003 Therapeutic Regimen Cytogen Corp License 1164 ProstaScint Capromab Pendetide 103608/0 10/28/1996 0.5 mg/mL Elan Pharmaceuticals License 1579 MYOBLOC Botulinum Toxin Type B 103846/0 12/8/2000 5,000 IU/mL Eli Lilly & Company License 1611 Xigris Drotrecogin alfa (Activated) 125029/0 11/21...
|
|
|
Tenecteplase TNKase clinical review page 95
author: CBER FDA
|
|
|
Tenecteplase TNKase clinical review page 94
author: CBER FDA
|
|
|
Tenecteplase TNKase clinical review page 93
author: CBER FDA
|
|
|
Tenecteplase TNKase clinical review page 92
author: CBER FDA
|
|
|
Tenecteplase TNKase clinical review page 91
author: CBER FDA
|
